ALLIANCE A082002 -A RANDOMIZED PHASE II/III TRIAL OF MODERN IMMUNOTHERAPY-BASED SYSTEMIC THERAPY WITH OR WITHOUT SBRT FOR PD-L1-NEGATIVE, ADVANCED NON-SMALL CELL LUNG CANCER
- Citation:
- Clin Lung Cancer vol 23 (5) e317-e320
- Year:
- 2022
- Type:
- Manuscript
- Funding:
- NCTN
- Endpoint:
- No-Endpoint
- Analysis:
- Trial-Description-Only
- Data Sharing:
- No-Data-Sharing
- Status:
- Presented/Published
- Citation Status:
- pmc-release
- Note:
- Methodological:
- No
- Biospecimen:
- No
- SDC:
- No
- Book Volume:
- Parents:
- None
- Children:
- None
- Program:
- OGC
- Primary Committee:
- Respiratory
- Sec. Committees:
- Pharmas:
- Grants:
- U10CA180821, U10CA180882, UG1CA232760, UG1CA233180, UG1CA233191, UG1CA233253, UG1CA233277, U10CA180820 (ECOG-ACRIN), U10CA180888 (SWOG), U10CA180868 (NRG)
- Corr. Author:
- Authors:
- STEVEN E. SCHILD XIAOFEI WANG CHRISTINE M. BESTVINA TERENCE WILLIAMS GREG MASTERS ANURAG SINGH THOMAS E. STINCHCOMBE JOSEPH K. SALAMA STEVEN WOLF TYLER ZEMLA NARJUST DUMA STEPHEN G. CHUN ARYA AMINI DAVID KOZONO COLLEEN WATT
- Networks:
- CA043, KANSAS, LAPS-IL057, LAPS-MA036, LAPS-MN026, LAPS-NC010, LAPS-TX035
- Study
- Alliance-A082002
- Multiple Studies, or Legacy Studies in Alliance Study:
- Phases:
- 2/3
- Keywords:
- Lung Cancer, stereotactic body radiation therapy, immunotherapy, chemotherapy